Guides & Research Breakdowns
Deeper dives into mechanism and evidence quality for the most-discussed compounds. General research summaries only — not dosing instructions.
BPC-157: What the Research Actually Shows
A look at the animal data behind the internet's favorite recovery peptide, and the gap between preclinical promise and human evidence.
GLP-1, GIP, and Triple Agonists: How the Weight-Loss Peptide Class Actually Works
Semaglutide, tirzepatide, and retatrutide all act on incretin hormone receptors, but each targets a different combination. Here's how the mechanisms differ.
Why CJC-1295 and Ipamorelin Are Almost Always Discussed Together
The pairing shows up constantly in peptide literature because the two compounds act on two different, complementary steps of the same GH-release pathway.
TB-500 and Thymosin Beta-4: What the Evidence Actually Covers
TB-500 is often discussed alongside BPC-157 for soft-tissue recovery. A 2026 scoping review shows where that evidence base actually sits — and where it doesn't.
PT-141 (Bremelanotide): The One Peptide in This Category the FDA Actually Approved
Most research peptides never see a completed human trial. PT-141 is the exception — it's an FDA-approved drug called Vyleesi. Here's what its approval trials actually showed, including the modest effect size.
Semax: The BDNF Mechanism, and Why the Evidence Base Stops at Russia's Border
Semax has been a prescription drug in Russia since 2011, with a genuine trail of published research behind it. Almost none of that research has been replicated outside Russia — here's what that gap does and doesn't mean.